RZLT

Rezolute is a pre-revenue, clinical-stage pharma whose entire equity value rests on one molecule, ersodetug, in two Phase 3 hyperinsulinism programs. There are no product sales in any year (revenue is blank FY2021–FY2025); losses widen every year — net loss went -$20.9M → -$41.1M → -$51.8M → -$68.5M → -$74.4M — and operating cash burn deepened 20.4% to -$69.1M. ROE is -45.9% and the accumulated deficit is -$404M. On the numbers alone there is nothing to value: no earnings, no sales, and EPS of -$0.98. This is a venture-style bet wearing a stock ticker, and the rubric's 'unknowable risk' test applies squarely.

What is genuinely good is the balance sheet. Liabilities/equity is just 0.08x, equity is $162M against only $13.4M of total liabilities, current assets ($171M) dwarf current liabilities ($11.9M), and cash sits at $94.1M — before the April 2025 underwritten offering that raised $103.5M gross plus a $4.2M private placement. So the company is funded through its stated catalysts and is not a bankruptcy risk. But that funding came at a steep price to holders: shares outstanding jumped 64% YoY to 90.8M, and the MD&A details ~25M new shares plus 6.9M pre-funded warrants at $3.25. Dilution is the recurring cost of staying alive here, and it will continue until (if) the drug is approved and sells.